Patents by Inventor Francis H. Martin

Francis H. Martin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES TO OPGL
    Publication number: 20200354464
    Abstract: Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are described.
    Type: Application
    Filed: June 18, 2020
    Publication date: November 12, 2020
    Applicants: AMGEN INC., AMGEN FREMONT INC.
    Inventors: William J. BOYLE, Francis H. MARTIN, Jose R. CORVALAN, C. Geoffrey DAVIS
  • ANTIBODIES TO OPGL
    Publication number: 20200131271
    Abstract: Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are described.
    Type: Application
    Filed: January 9, 2020
    Publication date: April 30, 2020
    Applicants: AMGEN INC., AMGEN FREMONT INC.
    Inventors: William J. BOYLE, Francis H. MARTIN, Jose R. CORVALAN, C. Geoffrey DAVIS
  • ANTIBODIES TO OPGL
    Publication number: 20170183417
    Abstract: Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are described.
    Type: Application
    Filed: September 2, 2016
    Publication date: June 29, 2017
    Applicant: AMGEN INC.
    Inventors: William J. BOYLE, Francis H. MARTIN, Jose R. CORVALAN, C. Geoffrey DAVIS
  • ANTIBODIES TO OPGL
    Publication number: 20150266952
    Abstract: Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are described.
    Type: Application
    Filed: February 12, 2015
    Publication date: September 24, 2015
    Inventors: William J. BOYLE, Francis H. MARTIN, Jose R. CORVALAN, C. Geoffrey DAVIS
  • Methods for treating bone loss with antibodies to OPGL
    Patent number: 8409578
    Abstract: Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are described.
    Type: Grant
    Filed: November 14, 2011
    Date of Patent: April 2, 2013
    Assignees: Amgen Inc., Amgen Fremont Inc.
    Inventors: William J. Boyle, Francis H. Martin, Jose R. Corvalan, C. Geoffrey Davis
  • Antibodies to OPGL
    Publication number: 20120087923
    Abstract: Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are described.
    Type: Application
    Filed: November 14, 2011
    Publication date: April 12, 2012
    Inventors: William J. Boyle, Francis H. Martin, Jose R. Corvalan, C. Geoffrey Davis
  • Polynucleotides encoding heavy and light chains of antibodies to OPGL
    Patent number: 8058418
    Abstract: Compositions comprising polynucleotides encoding heavy and light chains of antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of making such antibodies are described.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: November 15, 2011
    Assignees: Amgen Inc., Amgen Fremont Inc.
    Inventors: William J. Boyle, Francis H. Martin, Jose R. Corvalan, C. Geoffrey Davis
  • DNA encoding chimeric toxin peptide fusion proteins and vectors and mammalian cells for recombinant expression
    Patent number: 8043829
    Abstract: Disclosed is a composition of matter comprising a ShK toxin peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs encoding the inventive composition of matter, an expression vector comprising the DNA, and host cells comprising the expression vector. Methods of treating an autoimmune disorder and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed.
    Type: Grant
    Filed: October 25, 2007
    Date of Patent: October 25, 2011
    Assignee: Amgen Inc.
    Inventors: John K. Sullivan, Joseph G. McGivern, Leslie P. Miranda, Hung Q. Nguyen, Kenneth W. Walker, Shaw-Fen Sylvia Hu, Colin V. Gegg, Jr., Taruna Arora Khare, Beverly S. Adler, Francis H. Martin
  • Methods of using conjugated toxin peptide therapeutic agents
    Patent number: 7910102
    Abstract: Disclosed is a composition of matter comprising an OSK1 peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs encoding the inventive composition of matter, an expression vector comprising the DNA, and host cells comprising the expression vector. Methods of treating an autoimmune disorder and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed.
    Type: Grant
    Filed: October 25, 2007
    Date of Patent: March 22, 2011
    Assignee: Amgen Inc.
    Inventors: John K. Sullivan, Joseph G. McGivern, Leslie P. Miranda, Hung Q. Nguyen, Kenneth W. Walker, Shaw-Fen Sylvia Hu, Colin V. Gegg, Jr., Taruna Arora Khare, Beverly S. Adler, Francis H. Martin
  • Methods for identifying functional antibodies
    Patent number: 7884054
    Abstract: The invention provides methods for screening multimeric antibodies produced by mammalian cells to find those that exhibit a biological function. The methods can be used to screen large numbers of antibodies, which may be cell surface, secreted, or intracellular antibodies. Antibodies can be screened to find those that bind antigen more avidly or those that compete with a ligand that binds to the antigen for binding. Any biological function that can be tested in vitro can be used to screen the antibodies. Nucleic acids encoding the antibodies that exhibit the biological function can be obtained in a number of ways.
    Type: Grant
    Filed: December 21, 2004
    Date of Patent: February 8, 2011
    Assignee: Amgen Inc.
    Inventors: Chen Zhou, Wenyan Shen, Francis H. Martin
  • Conjugated toxin peptide therapeutic agents
    Patent number: 7820623
    Abstract: Disclosed is a composition of matter comprising an OSK1 peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs encoding the inventive composition of matter, an expression vector comprising the DNA, and host cells comprising the expression vector. Methods of treating an autoimmune disorder and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed.
    Type: Grant
    Filed: October 25, 2007
    Date of Patent: October 26, 2010
    Assignee: Amgen Inc.
    Inventors: John K. Sullivan, Joseph G. McGivern, Leslie P. Miranda, Hung Q. Nguyen, Kenneth W. Walker, Shaw-Fen Sylvia Hu, Colin V. Gegg, Jr., Taruna Arora Khare, Beverly S. Adler, Francis H. Martin
  • DNA encoding chimeric toxin peptide fusion proteins and vectors and mammalian cells for recombinant expression
    Publication number: 20090299044
    Abstract: Disclosed is a composition of matter comprising an OSK1 peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs encoding the inventive composition of matter, an expression vector comprising the DNA, and host cells comprising the expression vector. Methods of treating an autoimmune disorder and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed.
    Type: Application
    Filed: October 25, 2007
    Publication date: December 3, 2009
    Inventors: John K. Sullivan, Joseph G. McGivern, Leslie P. Miranda, Hung Q. Nguyen, Kenneth W. Walker, Shaw-Fen Sylvia Hu, Colin V. Gegg, JR., Taruna Arora Khare, Beverly S. Adler, Francis H. Martin
  • Methods of using conjugated toxin peptide therapeutic agents
    Publication number: 20090297520
    Abstract: Disclosed is a composition of matter comprising an OSK1 peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs encoding the inventive composition of matter, an expression vector comprising the DNA, and host cells comprising the expression vector. Methods of treating an autoimmune disorder and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed.
    Type: Application
    Filed: October 25, 2007
    Publication date: December 3, 2009
    Inventors: John K. Sullivan, Joseph G. McGivern, Leslie P. Miranda, Hung Q. Nguyen, Kenneth W. Walker, Shaw-Fen Sylvia Hu, Colin V. Gegg, JR., Taruna Arora Khare, Beverly S. Adler, Francis H. Martin
  • Conjugated toxin peptide therapeutic agents
    Publication number: 20090291885
    Abstract: Disclosed is a composition of matter comprising an OSK1 peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs encoding the inventive composition of matter, an expression vector comprising the DNA, and host cells comprising the expression vector. Methods of treating an autoimmune disorder and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed.
    Type: Application
    Filed: October 25, 2007
    Publication date: November 26, 2009
    Inventors: John K. Sullivan, Joseph G. McGivern, Leslie P. Miranda, Hung Q. Nguyen, Kenneth W. Walker, Shaw-Fen Sylvia Hu, Colin V. Gegg, JR., Taruna Arora Khare, Beverly S. Adler, Francis H. Martin
  • Antibodies to OPGL
    Publication number: 20090274688
    Abstract: Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are described.
    Type: Application
    Filed: October 30, 2007
    Publication date: November 5, 2009
    Inventors: William J. Boyle, Francis H. Martin, Jose R. Corvalan, C. Geoffrey Davis
  • Stem cell factor
    Publication number: 20080305074
    Abstract: Novel stem cell factors, oligonucleotides encoding the same, and methods of production, are disclosed. Pharmaceutical compositions and methods of treating disorders involving blood cells are also disclosed.
    Type: Application
    Filed: February 5, 2007
    Publication date: December 11, 2008
    Applicant: AMGEN INC.
    Inventors: Krisztina M. Zsebo, Robert A. Bosselman, Sidney V. Suggs, Francis H. Martin
  • Antibodies to OPGL
    Patent number: 7364736
    Abstract: Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are described.
    Type: Grant
    Filed: June 25, 2002
    Date of Patent: April 29, 2008
    Assignees: Amgen Inc., Amgen Fremont Inc.
    Inventors: William J. Boyle, Francis H. Martin, Jose R. Corvalan, C. Geoffrey Davis
  • SCF antibody compositions and methods of using the same
    Patent number: 7144731
    Abstract: Novel stem cell factors, oligonucleotides encoding the same, and methods of production, are disclosed. Pharmaceutical compositions and methods of treating disorders involving blood cells are also disclosed.
    Type: Grant
    Filed: January 28, 2003
    Date of Patent: December 5, 2006
    Assignee: Amgen Inc.
    Inventors: Krisztina M. Zsebo, Robert A. Bosselman, Sidney V. Suggs, Francis H. Martin
  • Method for increasing hematopoietic progenitor cells by stem cell factor
    Patent number: 6967029
    Abstract: Novel stem cell factors, oligonucleotides encoding the same, and methods of production, are disclosed. Pharmaceutical compositions and methods of treating disorders involving blood cells are also disclosed.
    Type: Grant
    Filed: August 21, 2000
    Date of Patent: November 22, 2005
    Assignee: Amgen Inc.
    Inventors: Krisztina M. Zsebo, Robert A. Bosselman, Sidney V. Suggs, Francis H. Martin
  • Method of stimulating growth of melanocyte cells by administering stem cell factor
    Patent number: 6852313
    Abstract: Novel stem cell factors, oligonucleotides encoding the same, and methods of production, are disclosed. Pharmaceutical compositions and methods of treating disorders involving blood cells are also disclosed.
    Type: Grant
    Filed: June 26, 2000
    Date of Patent: February 8, 2005
    Assignee: Amgen Inc.
    Inventors: Krisztina M. Zsebo, Robert A. Bosselman, Sidney V. Suggs, Francis H. Martin